$HYEX
HEALTHY EXTRACTS INC. Stock $hyex

$hyex Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000109690624001186 Filed on May 20, 2024

Income Statement

Concept	2024 Q1	2023 Q1
Revenue	$688.8K	$614.9K
YoY Change	12.01%	32.71%
Cost Of Revenue	$280.4K	$337.1K
YoY Change	-16.81%	143.08%
Gross Profit	$408.4K	$277.8K
YoY Change	46.98%	-14.43%
Gross Profit Margin	59.29%	45.18%
Selling, General & Admin	$470.4K	$683.0K
YoY Change	-31.13%	84.42%
% of Gross Profit	115.2%	245.83%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$550.00	$550.00
YoY Change	0.0%
% of Gross Profit	0.13%	0.2%
Operating Expenses	$470.4K	$683.0K
YoY Change	-31.13%	84.42%
Operating Profit	-$62.07K	-$405.2K
YoY Change	-84.68%	787.6%
Interest Expense	-$799.2K	-$174.0K
YoY Change	359.38%	-478.03%
% of Operating Profit
Other Income/Expense, Net	-$799.2K	-$174.0K
YoY Change	359.39%	-457.49%
Pretax Income	-$861.3K	-$579.2K
YoY Change	48.71%	-19341.2%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$861.3K	-$579.2K
YoY Change	48.71%	-19341.1%
Net Earnings / Revenue	-125.04%	-94.18%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.30	$0.00
COMMON SHARES
Basic Shares Outstanding		345.2M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$87.31K	$213.2K
YoY Change	-59.05%	131.01%
Cash & Equivalents	$87.31K	$213.2K
Short-Term Investments
Other Short-Term Assets	$205.8K
YoY Change
Inventory	$1.553M	$1.654M
Prepaid Expenses
Receivables	$24.06K	$135.4K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.870M	$2.003M
YoY Change	-6.63%	-9.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.760K	$4.950K
YoY Change	-44.24%	-30.77%
Goodwill	$193.3K	$193.3K
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$16.89K	$102.5K
YoY Change	-83.53%	506.99%
Total Long-Term Assets	$734.8K	$822.6K
YoY Change	-10.68%	11.29%
TOTAL ASSETS
Total Short-Term Assets	$1.870M	$2.003M
Total Long-Term Assets	$734.8K	$822.6K
Total Assets	$2.605M	$2.825M
YoY Change	-7.81%	-4.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$117.5K	$114.5K
YoY Change	2.65%	8.6%
Accrued Expenses	$206.5K	$85.87K
YoY Change	140.42%	215.24%
Deferred Revenue
YoY Change
Short-Term Debt	$1.102M	$1.084M
YoY Change	1.68%	203.1%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.453M	$1.510M
YoY Change	62.43%	199.75%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.453M	$1.510M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$2.453M	$1.510M
YoY Change	62.43%	199.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$19.26M	-$16.51M
YoY Change	16.69%
Common Stock	$354.5K	$345.5K
YoY Change	2.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$151.6K	$1.315M
YoY Change
Total Liabilities & Shareholders Equity	$2.605M	$2.825M
YoY Change	-7.81%	-4.2%

Cashflow Statement

Concept	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$861.3K	-$579.2K
YoY Change	48.71%	-19341.1%
Depreciation, Depletion And Amortization	$550.00	$550.00
YoY Change	0.0%
Cash From Operating Activities	$18.72K	-$310.3K
YoY Change	-106.03%	186.19%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$49.15K	$457.8K
YoY Change	-89.27%	-3511.42%
NET CHANGE
Cash From Operating Activities	$18.72K	-$310.3K
Cash From Investing Activities	$0.00	$0.00
Cash From Financing Activities	$49.15K	$457.8K
Net Change In Cash	$67.87K	$147.6K
YoY Change	-54.0%	-213.66%
FREE CASH FLOW
Cash From Operating Activities	$18.72K	-$310.3K
Capital Expenditures	$0.00	$0.00
Free Cash Flow	$18.72K	-$310.3K
YoY Change	-106.03%	208.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	000-55572
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	Healthy Extracts Inc.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-2594704
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	7375 Commercial Way
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 125
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Henderson
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89011
CY2024Q1	dei	City Area Code CityAreaCode	702
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	463-1004
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2963906	shares
CY2024Q1	us-gaap	Cash Cash	87312	usd
CY2023Q4	us-gaap	Cash Cash	19441	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24055	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	30440	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	1552814	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1626283	usd
CY2024Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	149274	usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	151931	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	56523	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	71583	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	1869978	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1899678	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2757	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3306	usd
CY2024Q1	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	521881	usd
CY2023Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	521881	usd
CY2024Q1	us-gaap	Deposits Assets DepositsAssets	16890	usd
CY2023Q4	us-gaap	Deposits Assets DepositsAssets	16890	usd
CY2024Q1	us-gaap	Goodwill Goodwill	193260	usd
CY2023Q4	us-gaap	Goodwill Goodwill	193260	usd
CY2024Q1	us-gaap	Other Assets OtherAssets	734787	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	735336	usd
CY2024Q1	us-gaap	Assets Assets	2604765	usd
CY2023Q4	us-gaap	Assets Assets	2635014	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	117515	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	116842	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	206452	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	215069	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	58906	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	65229	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9222	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	295795	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	361093	usd
CY2024Q1	fil	Notes Payable Related Party NotesPayableRelatedParty	178366	usd
CY2023Q4	fil	Notes Payable Related Party NotesPayableRelatedParty	83366	usd
CY2024Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	628045	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	608601	usd
CY2024Q1	us-gaap	Interest Payable Current InterestPayableCurrent	50647	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	64386	usd
CY2024Q1	fil	Accrued Interest Payable Related Party AccruedInterestPayableRelatedParty	6615	usd
CY2023Q4	fil	Accrued Interest Payable Related Party AccruedInterestPayableRelatedParty	2465	usd
CY2024Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	910779	usd
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	154150	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2453120	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1680424	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2963906	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2963906	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2954104	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2954104	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	354502	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	354492	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	19058075	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	18999770	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19260931	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18399673	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	151646	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	954590	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2604765	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2635014	usd
CY2024Q1	us-gaap	Sales Type Lease Revenue SalesTypeLeaseRevenue	688786	usd
CY2023Q1	us-gaap	Sales Type Lease Revenue SalesTypeLeaseRevenue	614943	usd
CY2024Q1	us-gaap	Revenues Revenues	688786	usd
CY2023Q1	us-gaap	Revenues Revenues	614943	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	280428	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	337102	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	280428	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	337102	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	408358	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	277841	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	470431	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	683029	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	470431	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	683029	usd
CY2024Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-42557	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-89060	usd
CY2024Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-756628	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-84908	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-799185	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-173968	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-861259	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-579157	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-861259	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-579157	usd
CY2024Q1	fil	Loss Per Share Basic And Diluted LossPerShareBasicAndDiluted	-0.3
CY2023Q1	fil	Loss Per Share Basic And Diluted LossPerShareBasicAndDiluted	-0.2
CY2024Q1	fil	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	2915410	shares
CY2023Q1	fil	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	2854290	shares
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	16000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-579157	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1315173	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	0	usd
CY2024Q1	fil	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits	0	usd
CY2024Q1	fil	Fair Value Of Unvested Restricted Stock Units FairValueOfUnvestedRestrictedStockUnits	58314	usd
CY2024Q1	fil	Issuance Of Common Stock Restricted Stock Units Issued IssuanceOfCommonStockRestrictedStockUnitsIssued	0	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-861259	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	151646	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-861259	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-579157	usd
CY2024Q1	fil	Depreciation And Amortization1 DepreciationAndAmortization1	549	usd
CY2023Q1	fil	Depreciation And Amortization1 DepreciationAndAmortization1	549	usd
CY2024Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	58314	usd
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	16000	usd
CY2024Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-756628	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-84908	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6385	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	29604	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-73469	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-164922	usd
CY2024Q1	fil	Increase Decrease In Offering Costs IncreaseDecreaseInOfferingCosts	2657	usd
CY2023Q1	fil	Increase Decrease In Offering Costs IncreaseDecreaseInOfferingCosts	0	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	0	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	32617	usd
CY2024Q1	fil	Increase Decrease In Right Of Use Asset Net IncreaseDecreaseInRightOfUseAssetNet	15060	usd
CY2023Q1	fil	Increase Decrease In Right Of Use Asset Net IncreaseDecreaseInRightOfUseAssetNet	0	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	673	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	23170	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-8617	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-8683	usd
CY2024Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-13739	usd
CY2023Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	17636	usd
CY2024Q1	fil	Increase Decrease In Accrued Interest Payable Related Party IncreaseDecreaseInAccruedInterestPayableRelatedParty	4150	usd
CY2023Q1	fil	Increase Decrease In Accrued Interest Payable Related Party IncreaseDecreaseInAccruedInterestPayableRelatedParty	0	usd
CY2024Q1	fil	Increase Decrease In Operating Lease Liability Current IncreaseDecreaseInOperatingLeaseLiabilityCurrent	-6324	usd
CY2023Q1	fil	Increase Decrease In Operating Lease Liability Current IncreaseDecreaseInOperatingLeaseLiabilityCurrent	0	usd
CY2024Q1	fil	Increase Decrease In Operating Lease Liability Noncurrent IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent	-9222	usd
CY2023Q1	fil	Increase Decrease In Operating Lease Liability Noncurrent IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	18724	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2024Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	19445	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	388888	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-342876	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2024Q1	us-gaap	Proceeds From Loan Originations1 ProceedsFromLoanOriginations1	0	usd
CY2023Q1	us-gaap	Proceeds From Loan Originations1 ProceedsFromLoanOriginations1	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	49146	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	490429	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	67871	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	147553	usd
CY2024Q1	fil	Payments For Repayment Of Convertible Debt PaymentsForRepaymentOfConvertibleDebt	0	usd
CY2023Q1	fil	Payments For Repayment Of Convertible Debt PaymentsForRepaymentOfConvertibleDebt	110535	usd
CY2024Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	118132	usd
CY2023Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	136705	usd
CY2024Q1	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-183430	usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	75370	usd
CY2024Q1	fil	Proceeds From Issuance Of Notes Payable Related Party ProceedsFromIssuanceOfNotesPayableRelatedParty	95000	usd
CY2023Q1	fil	Proceeds From Issuance Of Notes Payable Related Party ProceedsFromIssuanceOfNotesPayableRelatedParty	0	usd
CY2024Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	usd
CY2023Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19441	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65651	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	87312	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	213204	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font:10pt Times New Roman;margin:0"><b><i>Use of Estimates</i></b></p> <p style="font:10pt Times New Roman;margin:0"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:11pt Times New Roman;margin:0;color:#000000;text-align:justify"><span style="font-size:10pt">In regards to inventory write-offs and allowances, our Company determines the net realizable value by using the various factors as following: excess or slow-moving inventories (12 months or more of inventory on hand), expiration dates (within 12 months of the current reporting period), current and future product demand, production planning, and market conditions. If any of these factors are found in the reporting period, management will review each item and determine if any additional allowances or write-offs need to be made. A change in any of these variable’s factors could result in an adjustment to inventory. Management has provided for any risks in the current inventory allowance booked. </span></p> <p style="font:11pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">As for revenue adjustments for discounts, allowances and refunds, we treat each of these items differently. When it comes to revenue discounts, we will create the invoice for the product sold which will include any discounts given. These discounts usually happen for a short period of time for sales that we will offer around holidays. Due to the revenue being recognized once the order has shipped, less any applicable discount, we book this transaction at the net </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><span style="font-size:10pt">order transaction amount. In regards to allowances and refunds for revenue adjustments, due to our refund percentage is less than 1% we decided the need for an estimated adjustment for allowances and refunds was not material. If we do receive any returned orders, we will directly book those orders as refunds the day we receive the call from the customer requesting the refund. We will book the credit memo at the full value of the customer original order.</span></p>
CY2024Q1	fil	Inventory Allowances InventoryAllowances	1519532	usd
CY2023Q4	fil	Inventory Allowances InventoryAllowances	1611257	usd
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	2849557	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2998683	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	219502	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	225567	usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	3287	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	13290	usd
CY2024Q1	us-gaap	Inventory Gross InventoryGross	3072346	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	3237540	usd
CY2024Q1	fil	Inventory Allowances InventoryAllowances	1519532	usd
CY2023Q4	fil	Inventory Allowances InventoryAllowances	1611257	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	1552814	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1626283	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font:10pt Times New Roman;margin:0;text-align:justify"><b><i>Concentration</i></b></p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><span style="background-color:#FFFFFF">There is no concentration of revenue for the year ended December 31, 2023 and for the months ended March 31, 2024 because the revenue was earned from multiple customers.</span></p>
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	102011	usd
CY2023	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	154150	usd
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	154150	usd
CY2024Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	756629	usd
CY2024Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	910779	usd
CY2024Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	910779	usd
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	154150	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	102011	usd
CY2023	fil	Convertible Debt Issued ConvertibleDebtIssued	145067	usd
CY2023	fil	Derivative Liabilities Debt Premium DerivativeLiabilitiesDebtPremium	29167	usd
CY2023	fil	Convertible Debt Change In Fair Value Recognized In Operations ConvertibleDebtChangeInFairValueRecognizedInOperations	-83923	usd
CY2023	fil	Convertible Debt Converted ConvertibleDebtConverted	-38172	usd
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	154150	usd
CY2024Q1	fil	Convertible Debt Issued ConvertibleDebtIssued	0	usd
CY2024Q1	fil	Derivative Liabilities Debt Premium DerivativeLiabilitiesDebtPremium	0	usd
CY2024Q1	fil	Convertible Debt Change In Fair Value Recognized In Operations ConvertibleDebtChangeInFairValueRecognizedInOperations	756629	usd
CY2024Q1	fil	Convertible Debt Converted ConvertibleDebtConverted	0	usd
CY2024Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	910779	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	388888	usd
	us-gaap	Net Income Loss NetIncomeLoss	19260931	usd
CY2024Q1	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	0	usd
CY2023Q4	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	0	usd
CY2024Q1	us-gaap	Capital Leases Contingent Rental Payments Due CapitalLeasesContingentRentalPaymentsDue	5333	usd
CY2024Q1	fil	Capital Leases Contingent Rental Payments Due Next24 Months CapitalLeasesContingentRentalPaymentsDueNext24Months	5694	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	0	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y29D
CY2024Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.098	pure
CY2024Q1	fil	Right Of Use Assets Net Of Amortization RightOfUseAssetsNetOfAmortization	56523	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	58906	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	58906	usd
CY2024Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	0	usd
CY2024Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	0	usd
CY2024Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	52226	usd
CY2024Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5822	usd
CY2024Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	usd
CY2024Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	58048	usd
CY2024Q1	us-gaap	Receivable With Imputed Interest Discount ReceivableWithImputedInterestDiscount	858	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	58906	usd
CY2023	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	83920	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	38172	usd
CY2024Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-756629	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	102011	usd
CY2023	fil	Convertible Debt Issued ConvertibleDebtIssued	145067	usd
CY2023	fil	Derivative Liabilities Debt Premium DerivativeLiabilitiesDebtPremium	29167	usd
CY2023	fil	Convertible Debt Change In Fair Value Recognized In Operations ConvertibleDebtChangeInFairValueRecognizedInOperations	-83923	usd
CY2023	fil	Convertible Debt Converted ConvertibleDebtConverted	-38172	usd
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	154150	usd
CY2024Q1	fil	Convertible Debt Issued ConvertibleDebtIssued	0	usd
CY2024Q1	fil	Derivative Liabilities Debt Premium DerivativeLiabilitiesDebtPremium	0	usd
CY2024Q1	fil	Convertible Debt Change In Fair Value Recognized In Operations ConvertibleDebtChangeInFairValueRecognizedInOperations	756629	usd
CY2024Q1	fil	Convertible Debt Converted ConvertibleDebtConverted	0	usd
CY2024Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	910779	usd
CY2024Q1	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	241152	usd
CY2023Q1	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-162163	usd
CY2024Q1	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-241152	usd
CY2023Q1	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	162163	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	241152	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	162163	usd
CY2024Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	241152	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	162163	usd
CY2024Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2024Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	The Company effectuated a reverse stock split of 120-for-1 as of December 29, 2023
CY2023Q1	fil	Warrants Issued WarrantsIssued	61846	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	195180	shares
CY2023Q4	fil	Warrants Fully Vested WarrantsFullyVested	195180	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	132680	shares
CY2024Q1	fil	Warrants Fully Vested WarrantsFullyVested	132680	shares
CY2023Q4	fil	Unvested Compensation Related To Issuances Of Restricted Stock Units Fair Value1 UnvestedCompensationRelatedToIssuancesOfRestrictedStockUnitsFairValue1	423910	usd
CY2024Q1	fil	Unvested Compensation Related To Issuances Of Restricted Stock Units Fair Value1 UnvestedCompensationRelatedToIssuancesOfRestrictedStockUnitsFairValue1	60727	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0539	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0518	pure
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y8M12D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y8M12D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.96	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.065	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001096906-24-001186-index-headers.html	Edgar Link	pending
0001096906-24-001186-index.html	Edgar Link	pending
0001096906-24-001186.txt	Edgar Link	pending
0001096906-24-001186-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hyex-20240331.htm	Edgar Link	pending
hyex-20240331.xsd	Edgar Link	pending
hyex10q_1.jpg	Edgar Link	pending
hyex_ex31z1.htm	Edgar Link	pending
hyex_ex31z2.htm	Edgar Link	pending
hyex_ex32z1.htm	Edgar Link	pending
hyex_ex32z2.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
hyex-20240331_cal.xml	Edgar Link	unprocessable
hyex-20240331_def.xml	Edgar Link	unprocessable
hyex-20240331_lab.xml	Edgar Link	unprocessable
hyex-20240331_pre.xml	Edgar Link	unprocessable
hyex-20240331_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HYEX
HEALTHY EXTRACTS INC. Stock $hyex

2024 Q1 Form 10-Q Financial Statement

#000109690624001186 Filed on May 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HYEX HEALTHY EXTRACTS INC. Stock $hyex

2024 Q1 Form 10-Q Financial Statement

#000109690624001186 Filed on May 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HYEX
HEALTHY EXTRACTS INC. Stock $hyex